The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose

Author： Breccia Massimo   Alimena Giuliana  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.13, 2011-09, pp. : 2075-2087

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-α Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

By Reed Shelby D.   Anstrom Kevin J.   Li Yanhong   Schulman Kevin A.  

PharmacoEconomics, Vol. 26, Iss. 5, 2008-01 ,pp. : 435-446

Adis International

Access to resources Recommend Favorite

The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia

By Smolej Lukáš  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 1009-1017

Informa Healthcare

Access to resources Recommend Favorite

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

By  

Cancer, Vol. 121, Iss. 14, 2015-07 ,pp. : 2375-2382

Blackwell Publishing

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

By  

Current Cancer Drug Targets, Vol. 12, Iss. 4, 2012-04 ,pp. : 391-401

Bentham Science Publishers

Access to resources Recommend Favorite

Dasatinib Treatment for Imatinib Resistant or Intolerant Patients with Chronic Myeloid Leukaemia

By Li J   Xu G   Yu S   He L   Guo L  

The Journal of International Medical Research, Vol. 39, Iss. 2, 2011-03 ,pp. : 337-347

Field House Publishing

Access to resources Recommend Favorite